Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

This publication has 32 references indexed in Scilit:

• Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
  The Lancet Neurology, 2013
• The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials
  Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013
• Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency
  Brain Research, 2012
• Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial
  Journal of Neurology, Neurosurgery & Psychiatry, 2012
• Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
  The Lancet Neurology, 2010
• Mitochondria: A therapeutic target in neurodegeneration
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
• The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?☆
  Advanced Drug Delivery Reviews, 2009
• Lithium delays progression of amyotrophic lateral sclerosis
  Proceedings of the National Academy of Sciences, 2008
• Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases
  Nature, 2006
• A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
  New England Journal of Medicine, 1994